

**S3 Table.** Characteristics of patients treated with capmatinib

	Total (n=13)	Group A (GCN $\geq$ 10 or <i>MET</i> ex14) (n=8, 61.5%)	Group B (others) (n=5, 38.5%)	p- value
Age, median (range, yr)	64.0 (51-79)	70.0 (57-79)	64.0 (51-72)	0.120
Sex				
Male	13 (100)	8 (100)	5 (100)	
Female	0 (0)	0	0	
Histology				
Adenocarcinoma	10 (76.9)	7 (87.5)	3 (60.0)	0.365
Squamous cell carcinoma	2 (15.4)	1 (12.5)	1 (20.0)	
Other	1 (7.7)	0	1 (20.0)	
Stage				
III	3 (23.1)	2 (25.0)	1 (20.0)	> 0.99
IV	10 (76.9)	6 (75.0)	4 (80.0)	
ECOG PS				
0	2 (15.4)	2 (25.0)	0 (0)	0.487
1	11 (84.6)	6 (75.0)	5 (100)	
GCN				
Mean (range)	9.6 (3.3-22.8)	12.1 (5.0-22.8)	5.6 (3.3-8.5)	0.031
GCN $\geq$ 10	6 (46.2)	6 (75.0)	0 (0)	
GCN < 10	7 (53.8)	2 (25.0)	5 (100)	
Exon 14 skipping mutation				
Present	3 (33.3)	3 (42.9)	0 (0)	0.500
Absent	6 (66.7)	4 (57.1)	2 (100)	

Values are presented as number (%) unless otherwise indicated. ECOG PS, Eastern Cooperative Oncology Group performance status; GCN, gene copy number.